Drugs / Lispro Mix 50/50
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00971997 | Sep 2009 → Apr 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2011-06-24 | Eli Lilly and Company | Results Analysis Compares Cost-Effectiveness of Premixed Insulin Analogs to Long-Acting Insulin Analogs in the Long-Term Treatment of Type 2 Diabetes in the U.S. lilly.com ↗
Eli Lilly and Company (NYSE: LLY) today announced results from an analysis designed to evaluate the cost-effectiveness of insulin lispro mix 75/25 and insulin lispro mix 50/50 versus long-acting insulin analog (LAIA). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-06-24 | Eli Lilly and Company | Analysis Compares Cost-Effectiveness of Premixed Insulin Analogs to Long-Acting Insulin Analogs in the Long-Term Treatment of Type 2 Diabetes in the U.S. lilly.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lispro Mix 50/50 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00971997 ↗ |
| Modality | Protein / enzyme biologic | “insulin analog mixture” NCT00971997 ↗ |
| Route | Subcutaneous | “Administered subcutaneously” NCT00971997 ↗ |